Vertex pursues myotonic dystrophy with $250M Entrada dealBusiness, R&DVertex Pharmaceuticals agreed to a collaboration deal with the pre-clinical biotech Entrada Therapeutics, Thursday. The two companies announced a global partnership to develop intracellular Endosomal Escape Vehicle (EEV) therapeutics. Read more December 8, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/12/Vertex-Kidney-Disease-Drug-Proves-its-Worth-in-Phase-II-BioSpace-12-1-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-12-08 11:45:112022-12-08 12:05:48Vertex pursues myotonic dystrophy with $250M Entrada deal
